본문 바로가기
KERD
논문KCI 등재

알츠하이머병에서 아세틸콜린에스테라제 억제제에 대한 치료 반응과 관련된 요인

Factors Associated with Treatment Response to Acetylcholinesterase Inhibitors in Alzheimer’s Disease

이미지|김정란|한송이
대한생물치료정신의학회 (Korean Society Of Biological Therapies In Psychiatry)|2015.06|생물치료정신의학 (Journal of the Korean Society of Biological Therapies in Psychiatry)|제21권 제2호|pp. 113-121

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

인지CognitionDepression우울증알츠하이머병Alzheimer disease콜린에스테라제 억제제Cholinesterase inhibitors
주제분류정신과학

초록

Objectives：This study aimed to identify factors associated with patients’ improved scores on the Mini Mental State Examination(MMSE) improvement by comparing the total MMSE scores of patients with Alzheimer’s disease(AD) before and after acetylcholinesterase inhibitors(AChEIs) treatment. Methods：Data from fifty-three outpatients with AD were analyzed in this retrospective study. The patients received AChEIs and were assessed using cognitive function tests two times at 12-month intervals. The cognitive function assessments included the Clinical Dementia Rating(CDR) and neuropsychological tests of the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease(CERAD-K). Patients were assessed for depressive symptoms using a Revised Korean version of the Geriatric Depression Scale(GDS-KR). The patients with improved MMSE scores comprised the Responder group, whereas the patients with deteriorated or unimproved MMSE scores comprised the Non–Responder group. The demographic and neuropsychological factors between the two groups were analyzed using the Chi-square test, t-test and Mann-Whitney test. The paired t-test and Wilcoxon signed-rank test were used for comparing clinical responses within each group. Results：Seventeen patients were included in the Responder group and thirty-six patients were included in the Non–Responder group. The baseline GDS-KR scores were significantly higher in the Responder group than in the Non-Responder group(p=0.018). The GDS-KR scores significantly decreased in the Responder group after 12 months(p=0.048). There was no difference between the two groups across cognitive subdomains. Conclusion：This study suggests that cognitive improvement following AChEIs for AD is associated with the response of depressive symptoms.

Abstract

Objectives：This study aimed to identify factors associated with patients’ improved scores on the Mini Mental State Examination(MMSE) improvement by comparing the total MMSE scores of patients with Alzheimer’s disease(AD) before and after acetylcholinesterase inhibitors(AChEIs) treatment. Methods：Data from fifty-three outpatients with AD were analyzed in this retrospective study. The patients received AChEIs and were assessed using cognitive function tests two times at 12-month intervals. The cognitive function assessments included the Clinical Dementia Rating(CDR) and neuropsychological tests of the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease(CERAD-K). Patients were assessed for depressive symptoms using a Revised Korean version of the Geriatric Depression Scale(GDS-KR). The patients with improved MMSE scores comprised the Responder group, whereas the patients with deteriorated or unimproved MMSE scores comprised the Non–Responder group. The demographic and neuropsychological factors between the two groups were analyzed using the Chi-square test, t-test and Mann-Whitney test. The paired t-test and Wilcoxon signed-rank test were used for comparing clinical responses within each group. Results：Seventeen patients were included in the Responder group and thirty-six patients were included in the Non–Responder group. The baseline GDS-KR scores were significantly higher in the Responder group than in the Non-Responder group(p=0.018). The GDS-KR scores significantly decreased in the Responder group after 12 months(p=0.048). There was no difference between the two groups across cognitive subdomains. Conclusion：This study suggests that cognitive improvement following AChEIs for AD is associated with the response of depressive symptoms.

참고문헌 (43)

  1. Fratiglioni L, "Prevalence of Alzheimer's disease and other dementias in an elderly urban population: Relationship with age, sex, and education", Neurology, 41, pp.1886~1892 (1991)
  2. Selkoe DJ, "Cell biology of protein misfolding: The examples of Alzheimer’s and Parkinson’s diseases", Nat Cell Biol, 6, pp.1054~1061 (2004)
  3. Francis PT, "The cholinergic hypothesis of Alzheimer’s disease: A review of progress", J Neurol Neurosurg Psychiatry, 66, pp.137~147 (1999)
  4. Bullock R, "New drugs for Alzheimer’s disease and other dementias", Br J Psychiatry, 180, pp.135~139 (2002)
  5. Lanctôt KL, "Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis", CMAJ, 169, pp.557~564 (2003)
  6. Kaduszkiewicz H, "Cholinesterase inhibitors for patients with Alzheimer’s disease: Systematic review of randomised clinical trials", BMJ, 331, pp.321~327 (2005)
  7. Lanctôt KL, "Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease", J Psychiatry Neurosci, 28, pp.13~26 (2003)
  8. Mendiondo MS, "Modelling mini mental state examination changes in Alzheimer’s disease", Stat Med, 19, pp.1607~1616 (2000)
  9. Wattmo C, "Predictors of long-term cognitive outcome in Alzheimer’s disease", Alzheimers Res Ther, 3, pp.23~35 (2011)
  10. Tanaka M, "Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer’s disease", J Neurol Sci, 225, pp.135~141 (2004)
  11. Macgowan SH, "Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer’s disease", Int J Geriatr Psychiatry, 13, pp.625~630 (1998)
  12. Rigaud A-S, "Presence or absence of at least oneє 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer’s disease", Pharmacogenetics, 12, pp.415~420 (2002)
  13. Evans M, "Sustained cognitive improvement following treatment of Alzheimer’s disease with donepezil", Int J Geriatr Psychiatry, 15, pp.50~53 (2000)
  14. Wattmo C, "Progression of mild Alzheimer’s disease: Knowledge and prediction models required for future treatment strategies", Alzheimers Res Ther, 5, pp.44~58 (2013)
  15. 곽용태, "알츠하이머병에서의 우울증", Dementia and Neurocognitive Disorders(대한치매학회지), 13(2), pp.27~36 (2014), 대한치매학회[DOI]
  16. Lee HB, "Depression in Alzheimer’s disease: Heterogeneity and related issues", Biol Psychiatry, 54, pp.353~362 (2003)
  17. Lyketsos CG, "Treating depression in Alzheimer disease: Efficacy and safety of sertraline therapy, and the benefits of depression reduction: The DIADS", Arch Gen Psychiatry, 60, pp.737~746 (2003)
  18. Lyketsos CG, "Depression in Alzheimer’s disease: Overview and treatment", Biol Psychiatry, 52, pp.243~252 (2002)
  19. Spalletta G, "The role of persistent and incident major depression on rate of cognitive deterioration in newly diagnosed Alzheimer’s disease patients", Psychiatry Res, 198, pp.263~268 (2012)
  20. Farlow MR, "Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer’s disease", Am J Alzheimers Dis Other Demen, 25, pp.347~352 (2010)
  21. Song J, "Cognitive subdomain responses to galantamine in Alzheimer’s disease", J Nerv Ment Dis, 202, pp.253~259 (2014)
  22. Persson CM, "Changes in cognitive domains during three years in patients with Alzheimer’s disease treated with donepezil", BMC Neurol, 9, pp.7~18 (2009)
  23. Saumier D, "Cognitive predictors of donepezil therapy response in Alzheimer disease", Dement Geriatr Cogn Disord, 24, pp.28~35 (2007)
  24. Putt RVD, "Effectiveness of acetylcholinesterase inhibitors: diagnosis and severity as predictors of response in routine practice", Int J Geriatr Psychiatry, 21, pp.755~760 (2006)
  25. Lee JH, "Development of the Korean version of the consortium to establish a registry for Alzheimer’s disease assessment packet(CERAD-K) clinical and neuropsychological assessment batteries", J Gerontol B Psychol Sci Soc Sci, 57, pp.47~53 (2002)
  26. Ji Yang Kim, "Standardization of the Korean Version of the Geriatric Depression Scale: Reliability, Validity, and Factor Structure", PSYCHIATRY INVESTIGATION, 5(4), pp.232~238 (2008), 대한신경정신의학회
  27. Lee DY, "A normative study of the CERAD neuropsychological assessment battery in the Korean elderly", J Int Neuropsychol, 10, pp.72~81 (2004)
  28. Foster RH, "Donepezil", Pharmacoeconomics, 16, pp.99~114 (1999)
  29. Wattmo C, "Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease", BMC Neurol, 14, pp.173~182 (2014)
  30. Teri L, "Cognitive decline in Alzheimer’s disease: A longitudinal investigation of risk factors for accelerated decline", J Gerontol B Psychol Sci Soc Sci, 50, pp.49~55 (1995)
  31. Galasko DR, "Measuring cognitive change in a cohort of patients with Alzheimer’s disease", Stat Med, 19, pp.1421~1432 (2000)
  32. Wattmo C, "Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting", Dement Geriatr Cogn Disord, 26, pp.203~211 (2007)
  33. Wattmo C, "Longterm outcome and prediction models of activities of daily living in Alzheimer Disease with cholinesterase inhibitor treatment", Alzheimer Dis Assoc Disord, 25, pp.63~72 (2011)
  34. Miranda LF, "Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer’s disease and mixed dementia: a one-year naturalistic study", J Alzheimers Dis, 45, pp.609~620 (2015)
  35. Raschetti R, "A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer’s disease", Eur J Clin Pharmacol, 61, pp.361~368 (2005)
  36. Gustafsson M, "Psychotropic drug use among people with dementia-a sixmonth follow-up study", BMC Pharmacol Toxicol, 14, pp.56~64 (2013)
  37. Hanlon JT, "Benzodiazepine use and cognitive function among community-dwelling elderly", Clin Pharmacol Ther, 64, pp.684~692 (1998)
  38. McShane R, "Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up", BMJ, 314, pp.266~270 (1997)
  39. Assal F, "Neuropsychiatric symptoms in the dementias", Curr Opin Neurol, 15, pp.445~450 (2002)
  40. Panza F, "Late-life depression, mild cognitive impairment, and dementia: Possible continuum?", Am J Geriatr Psychiatry, 18, pp.98~116 (2010)
  41. Rao V, "The benefits and risks of ECT for patients with primary dementia who also suffer from depression", Int J Geriatr Psychiatry, 15, pp.729~735 (2000)
  42. Zahodne LB, "Coupled cognitive and functional change in Alzheimer’s disease and the influence of depressive symptoms", J Alzheimers Dis, 34, pp.851~860 (2013)
  43. Rosen WG, "A new rating scale for Alzheimer’s disease", Am J Psychiatry, 141, pp.1356~1364 (1984)

관련 논문AI추천

알츠하이머 치매 환자에서 치료 전 중증도에 따른 약물의 장기 치료 효과권인선, 김정란, 박유리, 서희원대한생물치료정신의학회 · 생물치료정신의학2021 · 제27권 제1호The Effect of Choline Acetyltransferase Genotype on Donepezil Treatment Response in Patients with Alzheimer’s Disease김기웅, 김도훈, 김문두, 김봉조, 김영훈, 김정란, 문석우, 우종인, 유승호, 윤종철, 이강욱, 이동영, 이정희, 이창욱, 이혜국, 장성만, 주진형, Nam-Jin Lee대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2015 · 제13권 제2호Single Photon Emission Computerized Tomography and Neuropsychological Tests That Predict a Good Response to Donepezil Therapy for Alzheimer’s Disease강경욱, 김동은, 김병채, 김자혜, 김태훈, 박경원, 송호천, 정광우, 정아리, 최승민, 하정민, Mony J. de Leon대한치매학회 · Dementia and Neurocognitive Disorders(대한치매학회지)2015 · 제14권 제3호알쯔하이머병과 소혈관성 치매에서 Donepezil 복용 후 K-MMSE의 변화와 의미 있는 K-MMSE 변화를 보이는 알쯔하이머병 환자의 특징김준, 곽용태, 이유상, 한일우대한생물정신의학회 · 생물정신의학2005 · 제12권 제2호순수 알츠하이머병 치매 환자군과 혼합성 치매 환자군에서 12개월간의 도네페질(Donepezil) 투여에 따른 치료 성적의 비교 평가강효신, 김도관, 김혜란, 문유진, 안인숙, 윤지혜, 이영민, 정재원, 황태영대한노인정신의학회 · 노인정신의학2010 · 제14권 제1호콜린분해효소 억제제의 사용 유무에 따른소혈관성 치매 환자의 임상 경과곽용태, 김경환, 석승한, 한일우대한신경과학회 · 대한신경과학회지2008 · 제26권 제3호

이 간행물의 다른 논문 (6건)

인터넷·게임 중독의 심리 사회적 접근이혁, 최태영pp. 65-72상동행동에 대한 정신의학적 접근법김기홍, 서민재pp. 73-80우울증의 생체 지표김혜금, 천은진pp. 81-94대학병원 응급실을 내원한 자살 시도자들의 특성 : 인구학적 및 정신사회적 자료원승희, 김지우, 이종훈, 김희철, 서완석, 이광헌pp. 95-104당뇨병을 가진 노인에서의 혈압과 인지기능 사이의 관련성제남주, 차보석, 이소영, 이철순, 서지영, 이동윤, 박철수, 김봉조, 이소진pp. 105-112
원문 보기